Healthcare Industry News: 5-FU
News Release - September 15, 2010
Saladax Biomedical Adds Industry Expert to Board of DirectorsGregory Critchfield, Formerly of Myriad Genetic Laboratories, Inc., Brings Broad Experience in Innovative Diagnostics
BETHLEHEM, Pa.--(Healthcare Sales & Marketing Network)--Saladax Biomedical, Inc. (www.saladax.com) announced today that Gregory Critchfield, M.D., M.S., has joined its board of directors. Critchfield has more than 20 years of experience in the diagnostic industry, most recently as President of Myriad Genetic Laboratories, Inc. Saladax develops novel companion diagnostics through partnerships with industry and is advancing its MYCARE™ line of diagnostic tests, each of which measure blood levels of drugs for cancer and central nervous system (CNS) disorders, providing physicians with guidance to personalize patient dosing for optimal efficacy.
“Greg’s expertise and knowledge is well aligned with Saladax’s driving mission to discover and develop diagnostic tests that enable personalized medicine,” said Dr. Salvatore J. Salamone, CEO of Saladax. “We welcome Greg to our Board of Directors and will look to benefit from his more than 20 years of industry leadership and his experience in successfully launching and commercializing innovative diagnostic services for predictive and prognostic medicine,” added Kevin Harter, Executive Chairman of the Board. “Greg’s contributions to the Board will be extremely valuable as Saladax continues to expand its product portfolio of diagnostics designed to improve patient outcomes.”
“Saladax is a personalized medicine company in the truest sense. I am excited to join the Saladax team,” said Critchfield. “The company’s mission is to improve patient outcomes and achieve economic savings in overall health care costs. Through industry partnerships and by offering its own line of MYCARE™ tests, Saladax is achieving these goals. Saladax’s elegant scientific approach for optimizing the dosing of drugs that patients receive is an important strategy for improving the health care received by potentially millions of patients worldwide.”
Critchfield spent more than 20 years in the diagnostics industry before retiring as President of Myriad Genetic Laboratories in March 2010. While President at Myriad, he built all aspects of the company’s operations, including scientific, medical and commercial strategies. He established the world’s highest quality, highest throughput clinical sequencing facility and launched seven novel medical molecular diagnostic products across a variety of technology platforms. Under Critchfield’s leadership, Myriad licensed a technology from Saladax that was developed and launched as OnDose™, a blood test for optimizing 5-FU dosing for patients in the US. Prior to his work at Myriad, Critchfield held several senior positions within the industry, including his time as Senior Vice President, Chief Medical and Science Officer, at Corning Clinical Laboratory/Quest Diagnostics.
About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic tests for the practical delivery of personalized medicine. The Company's products span all stages of development and address a variety of therapeutic areas, with an initial focus in oncology with its MYCARE™ portfolio. Saladax applies its validated technology platform to create tests that increase efficacy and reduce toxicity of existing and emerging therapeutics, on a patient by patient basis--because no two patients are alike.
For more information about Saladax, visit www.saladax.com or view our video at http://www.saladax.com/saladaxvideo. For more information on becoming a companion diagnostic partner, visit http://www.saladax.com/cdx.
Source: Saladax Biomedical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.